scholarly journals Absence of theERBB2 kinase domain mutation in lung adenocarcinomas in Korean patients

2005 ◽  
Vol 116 (4) ◽  
pp. 652-653 ◽  
Author(s):  
Jong Woo Lee ◽  
Young Hwa Soung ◽  
Su Young Kim ◽  
Won Sang Park ◽  
Suk Woo Nam ◽  
...  
Keyword(s):  
Kinase Domain ◽  
Korean Patients ◽  
Kinase Domain Mutation ◽  
Lung Adenocarcinomas

scholarly journals Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers

2010 ◽  
Vol 31 (5) ◽  
pp. 647-648 ◽  
Author(s):  
Yi-hua Sun ◽  
Rong Fang ◽  
Bin Gao ◽  
Xiang-kun Han ◽  
Jun-hua Zhang ◽  
...  
Keyword(s):  
Kinase Domain ◽  
Comparable Rate ◽  
Male And Female ◽  
Kinase Domain Mutation ◽  
Never Smokers ◽  
Lung Adenocarcinomas ◽  
Chinese Male ◽  
Egfr Kinase

scholarly journals Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4

PLoS ONE ◽  
2007 ◽  
Vol 2 (5) ◽  
pp. e426 ◽  
Author(s):  
Jenifer L. Marks ◽  
Michael D. McLellan ◽  
Maureen F. Zakowski ◽  
Alex E. Lash ◽  
Yumi Kasai ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Mutational Analysis ◽  
Kinase Domain ◽  
Kinase Domain Mutation ◽  
Lung Adenocarcinomas

ERBB2 kinase domain mutation in a gastric cancer metastasis

Apmis ◽  
2005 ◽  
Vol 113 (10) ◽  
pp. 683-687 ◽  
Author(s):  
JONG WOO LEE ◽  
YOUNG HWA SOUNG ◽  
SU YOUNG KIM ◽  
WON SANG PARK ◽  
SUK WOO NAM ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Metastasis ◽  
Kinase Domain ◽  
Kinase Domain Mutation

scholarly journals Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia

2016 ◽  
Vol 8 ◽  
pp. 2016016
Author(s):  
Massimo Breccia ◽  
Gioia Colafigli ◽  
Luisa Quattrocchi ◽  
Elisabetta Abruzzese ◽  
Giuliana Alimena
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Kinase Domain ◽  
Third Generation ◽  
Cutaneous Lesions ◽  
Advanced Phase ◽  
Kinase Domain Mutation

Ponatinib a third generation tyrosine kinase inhibitor, has been approved for all phases of disease in CML. In advanced phase, has been confirmed with a good efficacy in all type of resistance, including T315I kinase domain mutation. We here report activity of the drug in advanced phase with extramedullary localization.

scholarly journals Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation

2011 ◽  
Vol 2011 ◽  
pp. 1-4
Author(s):  
B. Uz ◽  
O. Bektas ◽  
E. Eliacik ◽  
H. Goker ◽  
Y. Erbilgin ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Chronic Phase ◽  
Kinase Domain ◽  
Current Treatment ◽  
Hematopoietic Stem ◽  
Abl Kinase ◽  
Kinase Domain Mutation ◽  
Kinase Mutation

The current treatment of chronic phase chronic myeloid leukemia (CML) consists of oral tyrosine kinase inhibitors (TKIs). However, high-risk CML may present with an aggressive course which may result in blastic crisis or a “difficult-to-manage” state with available treatments. The aim of this paper is to report a patient with complicated CML resistant to treatment and progressed despite the administration of bosutinib, imatinib mesylate, nilotinib, dasatinib, interferon alpha 2a, cytotoxic chemotherapy, and allogeneic hematopoietic stem cell transplantation. The striking point of this case story is that no Abl kinase domain mutation against TKIs has been detected during this very complicated disease course of CML. Meanwhile, challenging cases will always be present despite the hope and progress in CML in the TKI era.

scholarly journals ABL gene kinase domain mutation scanning by denaturing high performance liquid chromatography sequencing method

2011 ◽  
Vol 28 (2) ◽  
pp. 97-102 ◽  
Author(s):  
Yucel Erbilgin ◽  
Suzin Catal ◽  
Ahmet Emre Eskazan ◽  
Ozden Hatirnaz ◽  
Teoman Soysal ◽  
...  
Keyword(s):  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
High Performance ◽  
Kinase Domain ◽  
Mutation Scanning ◽  
Sequencing Method ◽  
Kinase Domain Mutation

scholarly journals EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment

Oncotarget ◽  
2015 ◽  
Vol 7 (3) ◽  
pp. 3367-3378 ◽  
Author(s):  
Hongjuan Zhang ◽  
Cheng Zhan ◽  
Ji Ke ◽  
Zhiqiang Xue ◽  
Aiqun Zhang ◽  
...  
Keyword(s):  
Kinase Domain ◽  
Lung Cancers ◽  
Hyperthermic Chemotherapy ◽  
Complete Treatment ◽  
Kinase Domain Mutation ◽  
Egfr Kinase
Sign in / Sign up

Export Citation Format

Share Document